

Cetuximab and Radiation - Locally Advanced Squamous Cell Carcinoma of the Head and Neck

(This form must be completed before the first dose is dispensed.)

1. Patient Profile

- * Surname:
- * Given Name:
- * OHIN: * Chart Number:
- * Postal Code:
- * Height (cm): * Weight (kg):
- * BSA (m²): * Gender: Male Female Other
- * Date of Birth:
Day Month Year
- * Site:
- * Attending Physician (MRP- Most Responsible Physician):
- Requested Prior Approval Yes * Patient on Clinical Trial Yes No
- Other (specify):
- Specify Arm:
 Standard of care arm Experimental arm
 Blinded / Unknown

Request prior approval for enrolment

- * Justification for Funding
-

2. Eligibility Criteria

The patient must meet the following criteria:

- a. The patient has locally or regionally advanced squamous cell carcinoma of the head and neck without distant metastases Yes

- b. The patient is unable to use cisplatin or carboplatin/5FU due to a medical contraindication (i.e., true platinum allergy or where the use of myelosuppressive drugs is contraindicated) Yes
- c. Cetuximab is used concurrently with acceptable radiation schedules that plan to intensify the delivery of radiation, such as accelerated radiotherapy Yes

3. Funded Dose

- Cetuximab 400 mg/m² IV loading dose, followed by 250 mg/m² IV weekly for 6 to 7 weeks
- Treatment is limited to the duration of radiation therapy

4. Supporting Documents

To ensure reimbursement of your claim, both the completed enrolment form and a copy of the required documentation (where applicable) must be submitted through CCO e-Claims.

Signature of Attending Physician (MRP- Most Responsible Physician):

.....
Day Month Year